Prescribing patterns of apixaban and rivaroxaban for extended-phase anticoagulant therapy
The majority of patients were prescribed full-dose rivaroxaban or apixaban for extended-phase anticoagulation, despite guidance suggesting use of a reduced dose. Prescribers may consider patient-specific risks for thrombosis and bleeding when selecting a dose of apixaban or rivaroxaban for VTE prevention.
Authors
- Ellen M. Uppuluri (ORCID: https://orcid.org/0000-0002-3306-2449)
- Mukti Patel
- Nancy L Shapiro
- Conny Mei
Institutions
- American Association of Colleges of Pharmacy (US)
- University of Illinois Chicago (US)
- University of Chicago Medical Center (US)
Publication Details
- Journal
- American Journal of Health-System Pharmacy
- Published
- 2026-02-03
- DOI
- https://doi.org/10.1093/ajhp/zxag026
- Primary Topic
- Atrial Fibrillation Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00